Pfizer Warning Letter Trips Up Sandoz/Momenta’s Expected Glatopa Launch
Executive Summary
Sandoz/Momenta’s generic of Teva’s 40 mg Copaxone appeared imminent – until apparently unrelated FDA warning letter regarding contract manufacturer Pfizer’s McPherson, Kan., plant put review on hold.
You may also be interested in...
How Pfizer Warning Letter Tarnished Sandoz/Momenta's Glatopa Launch
An FDA warning letter to a contract manufacturer, Pfizer, delayed Sandoz/Momenta's Glatopa 40 mg launch, reducing projected revenues and leading Momenta to consider selling assets.
How Pfizer Warning Letter Tarnished Sandoz/Momenta's Glatopa Launch
An FDA warning letter to a contract manufacturer, Pfizer, delayed Sandoz/Momenta's Glatopa 40 mg launch, reducing projected revenues and leading Momenta to consider selling assets.
How Pfizer Warning Letter Tarnished Sandoz/Momenta's Glatopa Launch
An FDA warning letter to a contract manufacturer, Pfizer, delayed Sandoz/Momenta's Glatopa 40 mg launch, reducing projected revenues and leading Momenta to consider selling assets.